Medication info

Telmisartan and Rosuvastatin Tablets 40/5 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Expired

MFDS item code 202101730 · Approved 2021.02.22

This product's status changed to Expired on 2026.02.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. The maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment when the dose is increased. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medications may be needed. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medication at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product with the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression; prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used in patients who need to take both telmisartan and rosuvastatin simultaneously. Telmisartan controls hypertension and reduces the risk of myocardial infarction, stroke, and cardiovascular disease mortality in high-risk patients. Rosuvastatin improves hypercholesterolemia and dyslipidemia, slows the progression of atherosclerosis, and reduces the risk of cardiovascular disease. It particularly helps reduce the risk of stroke, myocardial infarction, and artery revascularization in patients with cardiovascular risk factors. The combination of these two medications effectively manages hypertension and dyslipidemia, improving cardiovascular health.

How to take

Adult dose

This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. The maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment when the dose is increased. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medications may be needed. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medication at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product with the same amounts of each active ingredient) for convenience.

Precautions

This medication may pose significant risks, especially to the fetus and newborn when used during pregnancy, and should not be administered to pregnant women or those who may become pregnant. Patients with allergies to this drug, severe liver or kidney diseases, certain muscle disorders, and congenital lactose intolerance should not take this medication. Elderly patients or those with high potassium levels or impaired liver function, as well as patients with heart or gastrointestinal disorders, should use this medication cautiously and require regular monitoring during treatment. This drug may cause various side effects such as muscle pain, weakness, liver function abnormality, low blood pressure, dizziness, and digestive disorders, so any unusual symptoms should be reported to healthcare professionals immediately. In particular, if muscle-related symptoms or significant changes in blood test levels occur, the medication should be discontinued and a doctor should be consulted. Muscle and liver function tests are recommended before and during treatment. Drug interactions may occur when taken with other medications, so patients must inform their healthcare provider about any other drugs they are taking, especially when combined with certain diuretics, antihypertensives, anticoagulants, immunosuppressants, etc. This medication may cause drowsiness or dizziness when driving or operating machinery, caution is advised. Safety and effectiveness in children have not been established, thus it is not recommended for use in this population. In the event of an overdose, symptoms such as low blood pressure, dizziness, and kidney failure may appear, requiring immediate medical attention. This medication should be stored away from direct sunlight and kept out of reach of children, and it should not be transferred to any other container.

Side effects

Elevated ALT, elevated AST, elevated serum creatine phosphokinase (CPK), dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal rigidity, acne, nasopharyngitis, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, nonspecific gastrointestinal disorders, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver impairment, increased sweating, rash, erythema, vascular edema, drug rash, toxic epidermal necrolysis, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, asthenia, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, headache, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, reduced libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, myasthenia gravis, ocular myasthenia gravis, constipation, nausea, pancreatitis, myopathy, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.